---
title: "ExoSort Platform"
url: "https://neurodex.co/exosort-platform/"
type: "page"
published: "2025-08-22T17:57:13+00:00"
modified: "2026-06-22T17:50:36+00:00"
author: "ervin@a2z.rs"
---

###### our technology

# Proprietary ExoSort  Platform

   ![ExoSort technology](https://neurodex.co/wp-content/uploads/2026/06/Detection-Platforms-1024x576.jpg)

## More than 91% of RNA/protein  Require [NDEs](https://neurodex.co/exosomes/) for Blood Detection

### Alpha Synuclein (non-brain-specific)

80% of all genes are expressed in the brain, only 0.6% are highly specific to the brain, and an additional 9% are enriched in the brain. 90% of the genes that are expressed in the brain are not specific and can not serve as biomarkers.

     ![Alpha synuclein in brain](https://neurodex.co/wp-content/uploads/2025/08/Frame-3-e1755768646915-1024x474.png)

### NFL (brain-specific protein)

The ExoSort Platform offers increased specificity toward the brain, enabling the detection of differences in proteins that are disease-specific but not brain-specific, such as alpha-synuclein. While the ExoSort Platform does not provide a significant benefit for the analysis of NFL, it does enable the detection of alpha-synuclein pathology.

   [More about NFL](https://neurodex.co/nf-l/)     ![Statistical comparison of two groups](https://neurodex.co/wp-content/uploads/2025/08/Frame-4-e1755768815929-1024x436.png)

## NeuroDex Biomarker Panel: TDP43

        ![TDP-43](https://neurodex.co/wp-content/uploads/2025/08/Untitled-design-35-1024x436.png)

Assay qualification completed (below 20% assay variability). Successful collaboration with over 7 pharma. 

TDP43 is a key blood biomarker for ALS and FTD. Critical for clinical trials’ success.
Over 100 ongoing ALS clinical trials 

## NeuroDex Biomarker
for Parkinson’s Disease and Lewy Body

### Blood Neuron-derived EVs Alpha-synuclein concordance with CSF seeding assay

- Assay qualification completed (CV<15%)
- High accuracy of predicting CSF a-Syn seeding positivity
- Over 80% sensitivity and specificity with N=150 clinically diagnosed PD and LBD

     ![a-synuclein](https://neurodex.co/wp-content/uploads/2025/08/Screenshot_2-3.png)

Ongoing 1100 sample study from PPMI (Parkinson’s Progression Markers Initiative) supported by MJFF

    [!\[Tgen\](https://neurodex.co/wp-content/uploads/2025/08/image-16.png)](https://www.tgen.org/)

RNAseq of 1100 sample study completed (250 PD and 150 healthy, three time points each) in collaboration with TGEN (NIH funded). More than 90% QC success, high batch-to-batch reproducibility (R=0.93)

    [!\[The Michel J. Fox Foundation for parkinsons research\](https://neurodex.co/wp-content/uploads/2025/08/image-15.png)](https://www.michaeljfox.org/)         ![ExoSort Platform](https://neurodex.co/wp-content/uploads/2025/08/Untitled-design-20-1024x488.png)